The nation of Zimbabwe has turned down a major American health deal valued at $367m (272 million pounds) spanning five years because of the United States' request for sensitive information.
This move became public after a government memo from December was disclosed, which showed President Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesman later explained that the United States was requesting genetic material for research and commercial gain while was unwilling to share the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged further dialogue to find a agreement suitable to both sides so the country's critical HIV programme can continue.
Wider Context
This rejection comes after a comparable situation in Kenya, where a court halted a related health funding agreement following concerns were filed about the safety of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral agreements to boost transparency and responsibility.
As per statements, 16 nations in Africa have to date signed similar agreements, constituting over $18.3bn in new funding.
Details of the Rejected Agreement
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to share its genetic material and health information indefinitely, without any equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Effectively, our country would supply the raw materials for medical research without any certainty that the end products would be available to our people if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were upending frameworks previously set up through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This framework is intended to guarantee that when a nation contributes its information, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how subsequent co-operation might be designed in a way that respects the sovereignty and dignity of each country."
Health Experts Reaction
Medical experts stated it understood the official position, but urged that talks should continue given that a large portion of the country's HIV programmes were funded by foreign aid.
"If technical issues exist, such as those relating to information security or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," it commented.
The halted deal underscores the ongoing tensions between accepting much-needed foreign assistance and safeguarding a country's data in an increasingly interconnected world.